Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Supportive hemotherapy in anemias].

B Haustein, W Helbig

    Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
    |May 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Transfusions should be tailored to patient needs, prioritizing erythrocyte concentrates over whole blood to minimize risks. Washed or specialized preparations are reserved for specific clinical situations to ensure transfusion success.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

    Journal of cancer research and clinical oncology·2006
    Same author

    Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.

    Annals of hematology·2003
    Same author

    Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease.

    Bone marrow transplantation·2002
    Same author

    Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.

    Bone marrow transplantation·2001
    Same author

    Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.

    Advances in experimental medicine and biology·1999
    Same author

    Pre-treatment of peripheral blood progenitor cells with macrophage inflammatory protein-1alpha induces prolonged survival of early progenitor cells over 6 weeks of long-term culture.

    British journal of haematology·1999
    Same journal

    [Report on the Fifth International Congress on Blood Transfusion, Paris, 13 to 19 September 1954].

    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete·2014
    Same journal

    [Blood coagulation; literature from 1952 to 1954. VI].

    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete·2014
    Same journal

    [Blood coagulation; publications from 1952-1954. V].

    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete·2014
    Same journal

    [Blood coagulation from 1952-1954. IV].

    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete·2014
    Same journal

    [Report on the fourth congress of the European Gastroenterological Society in Paris, 27 June to 2 July 1954].

    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete·2014
    Same journal

    [The islands of Langerhans in pancreatic carcinoma].

    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete·2014
    See all related articles

    Area of Science:

    • Hematology
    • Transfusion Medicine

    Context:

    • Supportive hemotherapy requires precise application of blood products.
    • Minimizing transfusion side effects is crucial for patient safety.

    Purpose:

    • To outline guidelines for appropriate use of whole blood and erythrocyte concentrates.
    • To define indications for specialized erythrocyte preparations.

    Summary:

    • Whole blood transfusions are indicated only for significant blood loss.
    • Erythrocyte concentrates, preferably buffy-coat-free, are the standard for most transfusion needs.
    • Washed erythrocyte preparations are for managing transfusion reactions, while plasma-free, alloantigen-poor concentrates are for chronically transfused patients and graft recipients.

    Impact:

    Related Experiment Videos

    • Optimizes transfusion strategies, enhancing therapeutic efficacy.
    • Reduces the incidence of adverse transfusion reactions.
    • Improves outcomes for patients requiring repeated transfusions or immunosuppression.